Xu J - Search Results

1

DNA in serum extracellular vesicles is stable under different storage conditions.

Jin Y, Chen K, Wang Z, Wang Y, Liu J, Lin L, Shao Y, Gao L, Yin H, Cui C, Tan Z, Liu L, Zhao C, Zhang G, Jia R, Du L, Chen Y, Liu R, Xu J, Hu X, Wang Y. Jin Y, et al. Among authors: xu j. BMC Cancer. 2016 Sep 23;16(1):753. doi: 10.1186/s12885-016-2783-2. BMC Cancer. 2016. PMID: 27662833 Free PMC article.

2

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.

Xu JM, Han Y, Li YM, Zhao CH, Wang Y, Paradiso A. Xu JM, et al. BMC Cancer. 2006 Dec 16;6:288. doi: 10.1186/1471-2407-6-288. BMC Cancer. 2006. PMID: 17173694 Free PMC article. Clinical Trial.

3

[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

Xu JM, Li YM, Wang Y, Zhao CH, Yuan SJ, Yang WW, Li ZQ, Han Y, Azzariti A, Paradiso A. Xu JM, et al. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):578-82. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17236550 Chinese.

4

[Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].

Zhao CH, Yuan SJ, Wang Y, Ge FJ, Luo WD, Xu JM. Zhao CH, et al. Ai Zheng. 2007 Dec;26(12):1299-303. Ai Zheng. 2007. PMID: 18076790 Free article. Chinese.

5

[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].

Wang Y, Xu JM, Shen L, Xu N, Wang JW, Jiao SC, Zhang JS, Song ST, Li J, Bao HY, Yang L, Li F. Wang Y, et al. Among authors: xu n, xu jm. Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):913-6. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18478930 Chinese.

6

[Combination with SN-38 on human colon cancer LoVo cells].

Wang Y, Xu JM, Xu QZ, Zhou PK, Song ST. Wang Y, et al. Zhonghua Zhong Liu Za Zhi. 2009 Oct;31(10):746-851. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 20021826 Chinese.

7

[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].

Lin L, Xu JM, Wang Y, Ge FJ, Liu LJ, Zhao CH, Li SS, Liu JZ, Li ZQ. Lin L, et al. Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):786-90. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21163073 Clinical Trial. Chinese.

8

[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].

Wang Y, Xu JM, Liu JZ, Lin L, Ge FJ, Li SS, Liu LJ, Zhao CH. Wang Y, et al. Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):671-5. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22340047 Chinese.

9

[Clinical analysis of the current treatment status of gastric cancer in 636 patients].

Zhuang QX, Xu JM, Lin L, Ge FJ, Liu LJ, Wang Y, Zhao CH. Zhuang QX, et al. Zhonghua Zhong Liu Za Zhi. 2012 Apr;34(4):316-20. doi: 10.3760/cma.j.issn.0253-3766.2012.04.017. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 22781048 Chinese.

10

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM. Wang Y, et al. World J Gastroenterol. 2012 Dec 7;18(45):6635-44. doi: 10.3748/wjg.v18.i45.6635. World J Gastroenterol. 2012. PMID: 23236239 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66,911 results

Search Page

Filters